生物材料设计的创新，实现癌症治疗的 RNA 干扰疗法的成功。
Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.
机构信息
McKetta Department of Chemical Engineering, 200 E. Dean Keeton St. Stop C0400, Austin, TX, 78712, USA.
Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin, TX, 78712, USA.
出版信息
Adv Healthc Mater. 2021 Jul;10(13):e2100350. doi: 10.1002/adhm.202100350. Epub 2021 May 11.
Abstract
Gene regulation using RNA interference (RNAi) therapy has been developed as one of the frontiers in cancer treatment. The ability to tailor the expression of genes by delivering synthetic oligonucleotides to tumor cells has transformed the way scientists think about treating cancer. However, its clinical application has been limited due to the need to deliver synthetic RNAi oligonucleotides efficiently and effectively to target cells. Advances in nanotechnology and biomaterials have begun to address the limitations to RNAi therapeutic delivery, increasing the likelihood of RNAi therapeutics for cancer treatment in clinical settings. Herein, innovations in the design of nanocarriers for the delivery of oligonucleotides for successful RNAi therapy are discussed.
摘要
利用 RNA 干扰（RNAi）疗法进行基因调控已成为癌症治疗的前沿领域之一。通过向肿瘤细胞递送合成寡核苷酸来定制基因表达的能力改变了科学家治疗癌症的思维方式。然而，由于需要有效地将合成 RNAi 寡核苷酸递送到靶细胞，其临床应用受到限制。纳米技术和生物材料的进步开始解决 RNAi 治疗递药的局限性，增加了 RNAi 治疗在临床环境中治疗癌症的可能性。本文讨论了为成功的 RNAi 治疗设计用于递送寡核苷酸的纳米载体的创新。
相似文献
1
Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.生物材料设计的创新，实现癌症治疗的 RNA 干扰疗法的成功。
Adv Healthc Mater. 2021 Jul;10(13):e2100350. doi: 10.1002/adhm.202100350. Epub 2021 May 11.
2
Budding Alliance of Nanotechnology in RNA Interference Therapeutics.RNA 干扰治疗中的新兴纳米技术联盟。
Curr Pharm Des. 2018;24(23):2632-2643. doi: 10.2174/1381612824666180807113948.
3
Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.分子工程化的 siRNA 缀合物用于肿瘤靶向 RNAi 治疗。
J Control Release. 2022 Nov;351:713-726. doi: 10.1016/j.jconrel.2022.09.040. Epub 2022 Oct 7.
4
Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.肿瘤靶向多功能纳米颗粒用于 siRNA 递送：癌症治疗的新进展。
Adv Healthc Mater. 2014 Aug;3(8):1182-93. doi: 10.1002/adhm.201300607. Epub 2014 Feb 28.
5
Lipid-Based Nanocarriers for RNA Delivery.用于RNA递送的脂质基纳米载体
Curr Pharm Des. 2015;21(22):3140-7. doi: 10.2174/1381612821666150531164540.
6
Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers.基于外泌体的纳米载体作为 RNA 干扰治疗载体的最新进展。
Nanomedicine (Lond). 2017 Nov;12(21):2653-2675. doi: 10.2217/nnm-2017-0210. Epub 2017 Sep 29.
7
Theranostic Nanoparticles for RNA-Based Cancer Treatment.基于 RNA 的癌症治疗用治疗诊断纳米颗粒。
Acc Chem Res. 2019 Jun 18;52(6):1496-1506. doi: 10.1021/acs.accounts.9b00101. Epub 2019 May 28.
8
Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.用于递送基于合成RNA干扰疗法的阳离子液晶纳米颗粒。
Oncotarget. 2017 Jul 18;8(29):48222-48239. doi: 10.18632/oncotarget.18421.
9
Noncoding RNA for Cancer Gene Therapy.用于癌症基因治疗的非编码RNA
Recent Results Cancer Res. 2016;209:51-60. doi: 10.1007/978-3-319-42934-2_4.
10
The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.RNAi 疗法的潜力与进展：siRNA 分子的化学和结构修饰及生物相容纳米载体的应用。
J Control Release. 2014 Nov 10;193:113-21. doi: 10.1016/j.jconrel.2014.05.030. Epub 2014 May 24.
引用本文的文献
1
Research progress of novel anti-tumor drug formulations.新型抗肿瘤药物制剂的研究进展
Front Oncol. 2024 Dec 16;14:1507958. doi: 10.3389/fonc.2024.1507958. eCollection 2024.
2
Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.用于靶向三阴性乳腺癌治疗的小干扰RNA药物递送策略的进展
Bioengineering (Basel). 2024 Aug 14;11(8):830. doi: 10.3390/bioengineering11080830.
3
Liposome-based RNAi delivery in honeybee for inhibiting parasite .基于脂质体的RNA干扰技术在蜜蜂中用于抑制寄生虫
Synth Syst Biotechnol. 2024 Jul 18;9(4):853-860. doi: 10.1016/j.synbio.2024.07.003. eCollection 2024 Dec.
4
Emerging Perspectives on Prime Editor Delivery to the Brain.向大脑递送碱基编辑器的新观点
Pharmaceuticals (Basel). 2024 Jun 11;17(6):763. doi: 10.3390/ph17060763.
5
Gel/hydrogel-based in situ biomaterial platforms for cancer postoperative treatment and recovery.用于癌症术后治疗与恢复的基于凝胶/水凝胶的原位生物材料平台。
Exploration (Beijing). 2023 May 31;3(5):20220173. doi: 10.1002/EXP.20220173. eCollection 2023 Oct.
6
Development of Cationic Lipid LAH4-L1 siRNA Complexes for Focused Ultrasound Enhanced Tumor Uptake.阳离子脂质体 LAH4-L1siRNA 复合物的构建及其在聚焦超声增强肿瘤摄取中的应用。
Mol Pharm. 2023 May 1;20(5):2341-2351. doi: 10.1021/acs.molpharmaceut.2c00909. Epub 2023 Mar 29.
7
Combining 3D Printing and Microfluidic Techniques: A Powerful Synergy for Nanomedicine.结合3D打印与微流控技术：纳米医学的强大协同作用。
Pharmaceuticals (Basel). 2023 Jan 1;16(1):69. doi: 10.3390/ph16010069.
8
Overcoming barriers in non-viral gene delivery for neurological applications.克服神经应用中非病毒基因传递的障碍。
Nanoscale. 2022 Mar 10;14(10):3698-3719. doi: 10.1039/d1nr06939j.
9
Hydrogels and Hydrogel Nanocomposites: Enhancing Healthcare through Human and Environmental Treatment.水凝胶和水凝胶纳米复合材料：通过人类和环境处理来增强医疗保健。
Adv Healthc Mater. 2022 Apr;11(7):e2101820. doi: 10.1002/adhm.202101820. Epub 2021 Dec 11.
10
Targeting neurons in the tumor microenvironment with bupivacaine nanoparticles reduces breast cancer progression and metastases.用布比卡因纳米颗粒靶向肿瘤微环境中的神经元可减少乳腺癌的进展和转移。
Sci Adv. 2021 Oct 8;7(41):eabj5435. doi: 10.1126/sciadv.abj5435. Epub 2021 Oct 6.
本文引用的文献
1
Polymer nanocarriers for MicroRNA delivery.用于递送微小RNA的聚合物纳米载体
J Appl Polym Sci. 2020 Jul 5;137(25). doi: 10.1002/app.48651. Epub 2019 Nov 12.
2
Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA.用于 miRNA 脑部递释的混合脂质自组装纳米粒。
Int J Pharm. 2020 Oct 15;588:119693. doi: 10.1016/j.ijpharm.2020.119693. Epub 2020 Aug 2.
3
A promising approach to develop nanostructured lipid carriers from solid lipid nanoparticles: preparation, characterization, cytotoxicity and nucleic acid binding ability.一种有前途的从固体脂质纳米粒制备纳米结构脂质载体的方法：制备、表征、细胞毒性和核酸结合能力。
Pharm Dev Technol. 2020 Oct;25(8):936-948. doi: 10.1080/10837450.2020.1759630. Epub 2020 May 14.
4
Construction of core-shell tecto dendrimers based on supramolecular host-guest assembly for enhanced gene delivery.基于超分子主客体组装构建核壳结构树枝状 tecto 分子用于增强基因递送
J Mater Chem B. 2017 Nov 21;5(43):8459-8466. doi: 10.1039/c7tb02585h. Epub 2017 Oct 31.
5
Efficient co-delivery of microRNA 21 inhibitor and doxorubicin to cancer cells using core-shell tecto dendrimers formed via supramolecular host-guest assembly.通过超分子主客体组装形成的核壳型结构树状大分子用于 miR-21 抑制剂和阿霉素的协同递送至癌细胞。
J Mater Chem B. 2020 Apr 8;8(14):2768-2774. doi: 10.1039/d0tb00346h.
6
Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics.用于开发抗癌 miRNA 疗法的基于鞘磷脂的纳米系统（SNs）。
Pharmaceutics. 2020 Feb 22;12(2):189. doi: 10.3390/pharmaceutics12020189.
7
A Multifunction Lipid-Based CRISPR-Cas13a Genetic Circuit Delivery System for Bladder Cancer Gene Therapy.一种多功能脂质型 CRISPR-Cas13a 基因电路传递系统，用于膀胱癌基因治疗。
ACS Synth Biol. 2020 Feb 21;9(2):343-355. doi: 10.1021/acssynbio.9b00349. Epub 2020 Jan 10.
8
Ultrasmall nanostructured drug based pH-sensitive liposome for effective treatment of drug-resistant tumor.基于超小纳米结构药物的 pH 敏感脂质体，用于有效治疗耐药性肿瘤。
J Nanobiotechnology. 2019 Nov 29;17(1):117. doi: 10.1186/s12951-019-0550-7.
9
Screening of non-invasive miRNA biomarker candidates for metastasis of gastric cancer by small RNA sequencing of plasma exosomes.通过对血浆外泌体的小 RNA 测序筛选胃癌转移的非侵入性 miRNA 生物标志物候选物。
Carcinogenesis. 2020 Jul 10;41(5):582-590. doi: 10.1093/carcin/bgz186.
10
Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.通过同时进行的纳米颗粒介导的 PD-L1 抑制和免疫原性细胞死亡来重新编程对癌症的 T 细胞反应。
J Control Release. 2019 Dec 10;315:126-138. doi: 10.1016/j.jconrel.2019.10.047. Epub 2019 Oct 28.
Zotero 插件